Role of novel targeted therapies in the clinic
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030-4009, USA. rherbst@mdanderson.org
Abstract:
The number and variety of novel, molecular-targeted agents offers realistic hope for significant advances in cancer treatment. The potential of these new treatment approaches is unquestionable, but the reality is something that only thorough clinical evaluation and experience can reveal. Clinical experience of targeted therapies is at an early stage but it is likely that we will have an increasing number of treatment options available to us in the near future. This manuscript explores our current understanding of molecular-targeted therapies and considers: What approach should be used? (single vs multitarget agents); When should they be administered? (identifying the optimal point for intervention); How should they be used? (monotherapy or combination therapy regimens); and Who should we be giving them to? (acknowledging the need for patient selection).
Insights
Novel molecular-targeted therapies offer hope for cancer treatment advances. This review explores optimal approaches, timing, combinations, and patient selection for these emerging treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- The development of novel molecular-targeted agents presents significant potential for advancing cancer treatment.
- Current clinical experience with targeted therapies is limited but growing, with an increasing number of options anticipated.
Purpose of the Study:
- To explore the current understanding of molecular-targeted therapies.
- To address key questions regarding the optimal use of these agents in cancer care.
Main Methods:
- Review of current knowledge on molecular-targeted therapies.
- Discussion of strategic considerations for agent application.
Main Results:
- Molecular-targeted therapies are a rapidly evolving field with considerable promise.
- Key considerations include agent selection (single vs. multitarget), optimal timing of administration, appropriate use in monotherapy or combination regimens, and crucial patient selection.
Conclusions:
- Further clinical evaluation and experience are essential to fully realize the potential of targeted therapies.
- A strategic approach encompassing agent choice, timing, combination, and patient selection is vital for effective utilization.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Pharmacogenomics: Identification of New Drug Targets


